Enosi Therapeutics collaborates with Danuo Science Group.

M2 EQUITYBITES-July 6, 2022-Enosi Therapeutics collaborates with Danuo Science Group

(C)2022 M2 COMMUNICATIONS http://www.m2.com

Enosi Therapeutics, a Delaware Corporation that is focused on providing therapeutics for cancer and autoimmune diseases, announced on Tuesday that it has collaborated with Hong Kong-based Danuo Science Group.

The collaboration is aimed at further developing two products presently in Enosi's range for Greater China.

Under the collaboration, Enosi's Growth Factor Trap (EN-2000 Program) and TNFR1 Blocker (EN-1000 Program) were licensed. Both programs have the potential to be utilised as crossover drugs to treat cancer and autoimmune diseases.

Danuo is to provide USD5m in upfront licensing fees...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT